| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | AZGP1 |
| Uniprot No | P25311 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-298aa |
| 氨基酸序列 | ENQGGRYSLTYIYTGLSKHVEDVPAFQALGSLNDLQFFRYNSKDRKSQPM GLWRQVEGMEDWKQDSQLQKAREDIFMETLKDIVEYYNDSNGSHVLQGRF GCEIENNRSSGAFWKYYYDGKDYIEFNKEIPAWVPFDPAAQITKQKWEAE PVYVQRAKAYLEEECPATLRKYLKYSKNILDRQDPPSVVVTSHQAPGEKK KLKCLAYDFYPGKIDVHWTRAGEVQEPELRGDVLHNGNGTYQSWVVVAVP PQDTAPYSCHVQHSSLAQPLVGPWEAS |
| 预测分子量 | 56 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于AZGP1重组蛋白的模拟参考文献示例(内容为虚构，仅作格式参考)：
1. **《重组AZGP1蛋白的制备及其在脂肪代谢调控中的作用研究》**
作者：Chen L, et al.
摘要：本研究通过原核表达系统成功制备了重组AZGP1蛋白，并验证其通过激活AMPK信号通路抑制脂肪细胞分化的功能，为肥胖治疗提供潜在靶点。
2. **《AZGP1重组蛋白在胰腺癌诊断中的生物标志物潜力》**
作者：Wang Y, et al.
摘要：通过哺乳动物细胞表达系统获得高纯度AZGP1重组蛋白，临床样本分析显示其在胰腺癌患者血清中显著下调，提示其作为诊断标志物的可能性。
3. **《重组AZGP1蛋白的抗炎作用及机制解析》**
作者：Kim S, et al.
摘要：研究利用昆虫细胞表达系统生产功能性AZGP1重组蛋白，发现其通过抑制NF-κB通路减轻小鼠模型中的肺部炎症反应。
4. **《AZGP1重组蛋白与肿瘤细胞迁移的关联性研究》**
作者：Rodriguez M, et al.
摘要：通过体外实验证实重组AZGP1蛋白可降低乳腺癌细胞MMP-9表达水平，抑制肿瘤细胞侵袭转移能力。
---
注：以上内容为模拟示例，实际文献需通过PubMed、Web of Science等学术平台检索关键词"AZGP1 recombinant protein"或结合具体研究方向筛选。
AZGP1 (Alpha-2-Glycoprotein 1. Zinc-Binding), also known as zinc-α2-glycoprotein (ZAG), is a secreted protein encoded by the AZGP1 gene in humans. It belongs to the immunoglobulin superfamily and shares structural homology with major histocompatibility complex (MHC) class I molecules. AZGP1 is widely expressed in epithelial tissues, including the liver, adipose tissue, and prostate, and circulates in bodily fluids such as blood, urine, and breast milk.
Biologically, AZGP1 plays multifaceted roles in lipid metabolism, immune regulation, and cell adhesion. It binds zinc ions and fatty acids, functioning as an adipokine that promotes lipolysis in adipocytes, akin to the action of hormones like adiponectin. This metabolic activity links AZGP1 to energy homeostasis, making it a potential therapeutic target in obesity and diabetes. Additionally, AZGP1 is implicated in cancer biology, where it exhibits context-dependent roles. In prostate and breast cancers, reduced AZGP1 expression correlates with tumor progression and poor prognosis, suggesting tumor-suppressive functions. Conversely, its upregulation in cachexia-associated cancers may contribute to cancer-associated weight loss.
Recombinant AZGP1 protein is produced using expression systems like mammalian cells (e.g., HEK293 or CHO) to ensure proper post-translational modifications, including glycosylation. It serves as a critical tool for studying AZGP1's interactions with receptors (e.g as yet unidentified receptors mediating lipid mobilization), signaling pathways, and therapeutic potential. In research, it aids in elucidating mechanisms underlying metabolic disorders, cancer metastasis, and immune modulation. Clinically, recombinant AZGP1 is explored for diagnostic applications (e.g., biomarker assays) and therapeutic strategies targeting cachexia or metabolic syndromes. Its dual role in metabolism and disease underscores its biomedical significance.
×
